Methods of Treating the Metabolic Syndrome, NAFLD/NASH and Type 2 Diabetes

Abstract
Nonalcoholic fatty liver disease (NAFLD) has emerged as a major source of liver disease globally. Clinically, NAFLD describes a spectrum of hepatic events ranging from moderate lipid accumulation to more aggressive steatosis with associated inflammation, ballooning hepatocytes, fibrosis, cirrhosis, and, in some cases, hepatocellular carcinoma (HCC). The excessive accumulation of lipids is a major risk factor for disease progression from the clinically silent NAFLD to the inflammatory, fibrotic, and cirrhotic nonalcoholic steatohepatitis (NASH) stage. Thus, there is a need for methods of treating metabolic disorders.

UC Berkeley researchers have discovered compounds that can be used to treat people with metabolic diseases.

Website

https://techtransfer.universityofcalifornia.edu/NCD/32852.html?utm_source=AUTMGTP&utm_medium=webpage&utm_term=ncdid_32852&utm_campaign=TechWebsites

Contact Information

Name: Terri Sale

Email: terri.sale@berkeley.edu

Phone: 510-643-4219